No description yet.
Providence, RIFounded 2021
1 source · checked 1 time, last 1d ago
The Form D states that $2,000,000 was sold and identifies 12 investors, but names no investors or financing stage. Its 2026-10-30 date is the first sale date, not an announcement date.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Form D (equity, other) [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $2M | 2026-10-30 | not stated | No recent discussion |
1 source · checked 1 time, last 1d ago [ VERIFIED ] read against 1 source The Form D states that $2,000,000 was sold and identifies 12 investors, but names no investors or financing stage. Its 2026-10-30 date is the first sale date, not an announcement date. [ BUILT WITH ]·[ SEARCH ]from a Form D filing·[ SCRAPE ]1 page read: sec.gov·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ AGENT ]company research by the Firecrawl agent | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Investment | $125,000 | 2025-05-28 | not stated | |
| Seed | $350,000 | 2024-06 | not stated | |
Reach Neuro builds implantable spinal-cord-stimulation neurotechnology to restore shoulder, arm and hand movement for stroke survivors and people with other debilitating neurological disorders.
Reach Neuro is targeting a major unmet need: chronic stroke can leave people with permanent upper-limb impairment after conventional rehabilitation has stopped, while its implantable Avantis system is designed to restore voluntary shoulder, arm and hand movement by stimulating the spinal cord. Early results in seven participants, including functional gains and FDA Breakthrough Device designation, give the company a clinically meaningful basis for advancing a broader study and moving the technology toward clinics.
Checked against 9 sources yesterday
None named.
Also named as backers in company research: SOSV, IndieBio, Richard King Mellon Foundation, Angel Investor Forum, METIS Innovative, NIH, NEMIC New England Medical Innovation Center